• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Motzer on where pembrolizumab/lenvatinib fits in advanced RCC treatment paradigm


In an interview during the 2021 ASCO Annual Meeting Robert J. Motzer, MD, discussed where the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) fits into the treatment paradigm for advanced renal cell carcinoma (RCC), based on findings from the phase 3 CLEAR trial. In the study the combination reduced the risk of death by 34% versus sunitinib (Sutent) in the frontline RCC setting. Motzer is the Kidney Cancer Section Head, Genitourinary Oncology Service; and Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.